122 related articles for article (PubMed ID: 22044687)
1. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.
Linder N; Bützow R; Lassus H; Lundin M; Lundin J
Gynecol Oncol; 2012 Feb; 124(2):311-8. PubMed ID: 22044687
[TBL] [Abstract][Full Text] [Related]
2. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Linder N; Lundin J; Isola J; Lundin M; Raivio KO; Joensuu H
Clin Cancer Res; 2005 Jun; 11(12):4372-81. PubMed ID: 15958620
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells.
Linder N; Martelin E; Lundin M; Louhimo J; Nordling S; Haglund C; Lundin J
Eur J Cancer; 2009 Mar; 45(4):648-55. PubMed ID: 19112016
[TBL] [Abstract][Full Text] [Related]
4. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Lassus H; Staff S; Leminen A; Isola J; Butzow R
Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer.
Kim AW; Batus M; Myint R; Fidler MJ; Basu S; Bonomi P; Faber LP; Wightman SC; Warren WH; McIntire M; Arvanitis LD; Gattuso P; Xu X; Liptay MJ
Lung Cancer; 2011 Feb; 71(2):186-90. PubMed ID: 20570389
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
9. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.
Scheil-Bertram S; Tylus-Schaaf P; du Bois A; Harter P; Oppitz M; Ewald-Riegler N; Fisseler-Eckhoff A
Gynecol Oncol; 2010 Nov; 119(2):325-31. PubMed ID: 20728204
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer.
Daponte A; Kostopoulou E; Papandreou CN; Daliani DD; Minas M; Koukoulis G; Messinis IE
Anticancer Res; 2008; 28(3B):1905-10. PubMed ID: 18630479
[TBL] [Abstract][Full Text] [Related]
13. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
14. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
16. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
18. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716
[TBL] [Abstract][Full Text] [Related]
19. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
20. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
